FilingsTodayJohnson & Johnson
At a glance
Johnson & Johnson reported 2025 revenue of $94.19B, up 6% from $88.82B in 2024. Over 4 years since 2021 ($78.74B), that is growth of about 4.6% a year. 2025 was the highest revenue year in this period.
In the last 12 months 11 insiders reported 1 open-market purchase ($258K) and 15 sales ($150.7M). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $32.2M by CEO and Chairman of the Board Joaquin Duato on Aug 14, 2026. Net, insiders were sellers of $150.4M.
Johnson & Johnson filed 8 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), regulation fd disclosure (2), officer or director change (1) and shareholder vote results (1). The latest officer or director change was reported on Aug 4, 2026.
3 of the 20 investors tracked here held Johnson & Johnson at the last quarter end, worth $1.51B combined. It is the largest weight for National Pension Service (Korea) (0.9% of its portfolio), followed by Bridgewater Associates (0.7%). Added: National Pension Service (Korea). Reduced: Bridgewater Associates and Soros Fund Management.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $20.88B | $17.94B | $35.15B | $14.07B | $26.8B |
| Diluted EPS | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Dividend per share | $4.19 | $4.45 | $4.70 | $4.91 | $5.14 |
Fiscal year ends Jan 3 · incorporated in NJ
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined